CURTIN UNIVERSITY

Orthocell's Remplir™ Achieves Milestone in FDA Regulatory Study for Nerve Repair

6 months ago

• Orthocell has successfully completed a pivotal FDA regulatory study for Remplir™, validating its safety and efficacy in peripheral nerve repair. • The study demonstrated that Remplir™ facilitated effective nerve regeneration, restoring motor and sensory functions comparable to an FDA-cleared control device. • Orthocell plans to submit its marketing application this month, with FDA clearance anticipated in the first quarter of the New Year, targeting the $1.6 billion US nerve repair market. • Clinical data showed that 85% of nerve repairs using Remplir™ achieved functional recovery, supporting its adoption in Australia, New Zealand, and Singapore.

Imugene Expands CAR T-Cell and Oncolytic Virotherapy Trials in Australia and the US

6 months ago

• Imugene is broadening its clinical trial programs for CAR T-cell therapy and oncolytic virotherapy across Australia and the United States. • The expansion aims to accelerate the development of novel cancer treatments, leveraging innovative immunotherapeutic approaches. • These trials will assess the safety and efficacy of Imugene's technologies in diverse patient populations and cancer types. • The company seeks to address unmet needs in cancer therapy by enhancing the body's immune response against tumors.

Deferiprone Fails to Improve Cognition in Early Alzheimer's Trial, Raises Concerns

6 months ago

• A clinical trial investigating deferiprone, an iron chelator, in patients with mild cognitive impairment or early Alzheimer's, showed reduced iron levels in the hippocampus but accelerated cognitive decline. • The 12-month study randomized 81 participants to either deferiprone (15 mg/kg twice daily) or placebo and assessed cognitive function, including memory and executive function. • While deferiprone effectively lowered iron levels in the hippocampus, patients receiving the drug experienced a worsening of executive function compared to the placebo group. • Researchers suggest that lowering iron levels with deferiprone may be detrimental for individuals with early Alzheimer's disease, warranting caution in its potential therapeutic use.

Recce Pharmaceuticals' Topical Gel R327G Reaches Midpoint in Phase II Trial

7 months ago

• Recce Pharmaceuticals has reached the midpoint in its Phase II clinical trial for topical gel R327G, aimed at treating skin infections. • The trial assesses the safety and efficacy of R327G in patients with infected skin wounds, a potential alternative to traditional antibiotics. • R327G represents a novel class of synthetic anti-infectives, designed to combat multi-drug resistant bacteria and address unmet medical needs. • The company anticipates interim data from the Phase II trial, which could provide insights into the gel's clinical potential.